Sharon Townson - 02 Jan 2026 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role: Chief Scientific Officer
Signature: /s/ Markus Warmuth, Attorney-in-Fact
Issuer symbol: GLUE
Transactions as of: 02 Jan 2026
Net transactions value: -$47,861
Form type: 4
Filing time: 05 Jan 2026, 16:04:07 UTC
Previous filing: 06 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Townson Sharon	Chief Scientific Officer	MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON	/s/ Markus Warmuth, Attorney-in-Fact	05 Jan 2026	0001855689

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GLUE	Common Stock	Award		+35,000	+97%		71,000	02 Jan 2026	Direct	F1
transaction	GLUE	Common Stock	Sale	$47,861	-3,155	-4.4%	$15.17	67,845	05 Jan 2026	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLUE	Stock Option (Right to Buy)	Award	$0	+158,000		$0.000000	158,000	02 Jan 2026	Common Stock	158,000	$15.31	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2	Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.